D&A at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's D&A?
- MoonLake Immunotherapeutics (MLTX) reported D&A of $845K in Q1 2026.
- How has MoonLake Immunotherapeutics's D&A changed year-over-year?
- MoonLake Immunotherapeutics's D&A increased by 123.5% year-over-year, from $378K to $845K.
- What is the long-term trend for MoonLake Immunotherapeutics's D&A?
- Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's D&A has grown at a 151.3% compound annual growth rate (CAGR), from $164.78K to $2.62M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.